ClinicalTrials.gg
Sign In

Neurodawn Pharmaceutical Co., Ltd. clinical trials

The registry lists 8 studies whose lead sponsor is Neurodawn Pharmaceutical Co., Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 28, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Get an email when these change. Save the Neurodawn Pharmaceutical Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Pipeline: 8 programmes

Each programme counted once, however many studies or names it has. 8 have a study Neurodawn Pharmaceutical Co., Ltd. leads, registered in the last two years.

Phase 15
Phase 22
Phase 31
Phase 40approved, new studies

Phase 3 programmes

1
Programme
Y-6 tabletPhase 3 · 1 live · Infarction
How we know

Read from the registry as written: no join or match was needed.

All 8 programmes

Programme
Y-6 tabletPhase 3 · 1 live · Infarction
How we know

Read from the registry as written: no join or match was needed.

RK-4 injectionPhase 2 · 1 live · Ischemic Stroke
How we know

Read from the registry as written: no join or match was needed.

Y-4 tablesPhase 2 · 1 live · Neuralgia, Postherpetic
How we know

Read from the registry as written: no join or match was needed.

PregabalinYHD1119Phase 1 · 1 live · Neuralgia
How we know
  1. One programme: YHD1119Judged by our rule (version e43f102): the same study entry names both · 2026-11-14Evidence: NCT02783638: “YHD1119” (other names: Pregabalin 300mg)
  2. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies Neurodawn Pharmaceutical Co., Ltd. leads of it also tests Y-4 tablet.Evidence: NCT07618715: given with Y-4 tablet
  3. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies Haisco Pharmaceutical Group Co., Ltd. leads of it also tests crisugabalin.Evidence: NCT06490484: given with crisugabalin
  4. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies H. Lundbeck A/S leads of it also tests Lu AG06474.Evidence: NCT06077786: given with Lu AG06474
  5. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies CrystalGenomics, Inc. leads of it also tests CG100649.Evidence: NCT05370716: given with CG100649
  6. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies Boehringer Ingelheim leads of it also tests BI 1026706.Evidence: NCT02037165: given with BI 1026706
  7. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies Bristol-Myers Squibb leads of it also tests BMS-954561.Evidence: NCT01314222: given with BMS-954561
  8. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 25 companies; each of the 1 studies Eli Lilly and Company leads of it also tests duloxetine.Evidence: NCT01089556: given with duloxetine
RiluzolePhase 1 · 1 live · Amyotrophic Lateral Sclerosis
How we know
  1. One programme: BHV0223Judged by our rule (version e43f102): the same study entry names both · 2026-11-14Evidence: NCT03520517: “BHV-0223”
  2. alongsideJudged by our rule (version e43f102): given-alongside · 2026-11-14Approved and tested by 5 companies; each of the 1 studies Neurodawn Pharmaceutical Co., Ltd. leads of it also tests Y-4 tablet.Evidence: NCT07618715: given with Y-4 tablet

3 more — sign in to see them all, free.

“Registry” is the highest phase of Neurodawn Pharmaceutical Co., Ltd.’s own registered studies; “Neurodawn Pharmaceutical Co., Ltd. says” is its pipeline, which lists phases by indication. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Neurodawn Pharmaceutical Co., Ltd.’s studies test, most open studies first — 2 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

All 8 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now563%Not yet recruiting 4 · Recruiting 1
  • Completed338%

Phase

  • Phase 16
  • Phase 23
  • Phase 31

Where

  • China5
  • United States2

Over the years

  1. 425
  2. 426

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Neurodawn Pharmaceutical Co., Ltd..

  • Neurodawn Pharmaceutical Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies

Studies

Recruiting first, then most recently updated. Showing 8 of 8.